Real-World Results of Post-Surgery EGFR-TKI Treatment in EGFR-Mutated Lung Cancer
Follows adults with early EGFR-mutated lung cancer treated with EGFR-TKI after surgery.
Key facts
- Who runs it
- AstraZeneca
- Where
- Beijing, Chengdu, Fuzhou, Guangzhou, Nanchang, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xi'an, Xuzhou, and Zhengzhou, ChinaSee the 13 sites
- Trial code
- Registry title
- Real-World Outcomes of Resected EGFR-Mutated NSCLC Patients Treated With Adjuvant EGFR-TKI in China
- Status
- Recruiting
- People taking part
- 2,000 people, planned
- Started
- 22 Jun 2026
- Expected to end
- 30 Jun 2031
- Type of study
- Observational
- Record updated
- 13 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The study includes adults with early-stage non-small cell lung cancer (NSCLC) who started an EGFR-TKI medicine after surgery between July 1st, 2023 and June 30th, 2026.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- NSCLC diagnosed as stage IB-III on or before the index date
- Earlier treatment
- Started adjuvant EGFR-TKI treatment from July 1st, 2023 to June 30th, 2026
- Biomarker or test result
- EGFR-mutated NSCLC (named in the title and summary)
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Diagnosed stage IB-III NSCLC on or prior to the index date
- Initiated adjuvant EGFR-TKI from July 1st, 2023 to June 30th, 2026
Where in China
- BeijingHospital not named in the registryNot yet recruiting
- ChengduHospital not named in the registryNot yet recruiting
- FuzhouHospital not named in the registryNot yet recruiting
- GuangzhouHospital not named in the registryTaking people
- NanchangHospital not named in the registryNot yet recruiting
- ShanghaiHospital not named in the registryNot yet recruiting
- ShenyangHospital not named in the registryNot yet recruiting
- ShijiazhuangHospital not named in the registryNot yet recruiting
- TianjinHospital not named in the registryNot yet recruiting
- WuhanHospital not named in the registryNot yet recruiting
- Xi'anHospital not named in the registryNot yet recruiting
- XuzhouHospital not named in the registryNot yet recruiting
- ZhengzhouHospital not named in the registryNot yet recruiting
About the trial
What the trial wants to find out
This is a multi-centre, observational study, with retrospective data collection and prospective active follow-up. The aim is to measure the treatment pattern and real-world outcomes of EGFR-TKI as an adjuvant therapy in patients with early-stage EGFR-mutated NSCLC. The study period ranges from July 1st, 2022 to June 30th, 2031. Approximately 2,000 patients will be enrolled from 15 sites in China.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Real-World Outcomes of Resected EGFR-Mutated NSCLC Patients Treated With Adjuvant EGFR-TKI in China
- Plain-language title
- Real-World Results of Post-Surgery EGFR-TKI Treatment in EGFR-Mutated Lung CancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 13 August 2026